Clinical trial
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria
NCT00425607 · Monica E. Kleinman, Other · Completed
Key facts
| NCT number | NCT00425607 |
|---|---|
| Title | Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria |
| Official title | An Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies |
| Lead sponsor | Monica E. Kleinman, Other |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Progeria, Hutchinson-Gilford Syndrome |
| Intervention type | Drug |
| Interventions | Lonafarnib |
| Enrollment | 29 |
| Start date | May 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Jan 23, 2007 |
| Last update posted | Jun 25, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: